Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pursuit Of R&D Efficiency Continues As Regulatory Options Expand In 2013 – Tufts CSDD

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Cutting non-core procedures – such as those supporting exploratory endpoints – from study budgets could save the industry $6 billion a year in drug development costs, the Tufts Center for the Study of Drug Development suggests in its 2013 industry outlook report.

You may also be interested in...



Breakthrough Status May Not Be So Groundbreaking, Recent Reviews Indicate

A look at some of FDA’s novel drug approvals analyzed in Pharmaceutical Approvals Monthly’s 2012 series of drug review profiles suggests that the agency has already ushered through several approvals that could be models for the new “breakthrough” designation created by the FDA Safety and Innovation Act.

AstraZeneca Teams With Vanderbilt In Neuroscience Pact

Vanderbilt University’s neuroscience research group reaches its latest agreement with a pharma, this one covering compounds that treat symptoms of Alzheimer’s disease and schizophrenia by modulating a receptor in new ways.

Thinking Through “Breakthrough”: Panel Discussion at the FDA/CMS Summit for Biopharma Executives

During The RPM Report’s FDA/CMS Summit for Biopharma Executives December 10, Office of New Drugs Director John Jenkins and Genzyme Senior Policy Advisor Kay Holcombe discussed the dynamics of Breakthrough Therapy during a panel discussion moderated by The RPM Report’s Kate Rawson. Here is a transcript of that discussion.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS005234

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel